The reliability of evidential pluralism in drug regulation

Synthese 204 (1):1-23 (2024)
  Copy   BIBTEX

Abstract

The aim of this paper is to shed light on and critically evaluate the potential impact of evidential pluralism in the realm of pharmaceutical regulation. In the complex landscape of drug evaluation and approval, the role of evidence is pivotal. Firstly, we delve into the role of evidence of mechanisms within drug regulation, with a particular focus on the Accelerated Approval pathway administered by the US Food and Drug Administration. Our analysis reveals that this program, in practice, closely resembles a pluralistic approach to evidence. Secondly, we undertake a thorough examination of the reliability of evidential pluralism within the context of drug regulation. We dissect and discuss the open-cases approach recently put forth by Sung and Holman. While acknowledging its potential merits, we also identify and articulate significant limitations inherent in this approach. Finally, we propose an alternative empirical approach that centres on the real-world outcomes of regulatory programs.

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 102,141

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Mifepristone Paternalism at the FDA.Jordan Paradise - 2023 - Journal of Law, Medicine and Ethics 51 (3):554-559.

Analytics

Added to PP
2024-07-17

Downloads
12 (#1,387,228)

6 months
12 (#321,633)

Historical graph of downloads
How can I increase my downloads?

Author Profiles

Saúl Pérez-González
Universitat de Valencia

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references